(2026). Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL. Rare Cancers and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL."
Rare Cancers and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL."
Rare Cancers and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.